@article{MAKHILLRJMS20082511644,
    title = {Anti-Proliferation of MDA-MB-231 Human Breast Tumour Cells by Arsenic Trioxide via Induction of Apoptosis},
    journal = {Research Journal of Medical Sciences},
    volume = {2},
    number = {5},
    pages = {236-243},
    year = {2008},
    issn = {1815-9346},
    doi = {rjmsci.2008.236.243},
    url = {https://makhillpublications.co/view-article.php?issn=1815-9346&doi=rjmsci.2008.236.243},
    author = {Lin-Li Zhou,Judy Yuet-Wa Chan,Jun Wang and},
    keywords = {Arsenic trioxide,breast tumour,MDA-MB-231,apoptosis},
    abstract = {Arsenic Trioxide (As<SUB>2</SUB>O<SUB>3</SUB>) has been explored for its use as medicine in both Western and Chinese societies. In 1990s, As<SUB>2</SUB>O<SUB>3</SUB> was reported to treat patients with acute promyelocytic leukemia (APL). Until recently, research on other solid tumour cells was emerged. In the present study, the mechanism of As<SUB>2</SUB>O<SUB>3</SUB> treatment of human breast tumour MDA-MB-231 cells was investigated. It was found that As<SUB>2</SUB>O<SUB>3</SUB> inhibited the cell proliferation of MDA-MB-231 cells in a time- and dose-dependent manner. Mechanistic study indicated that the inhibition was induced via cell cycle arrest and apoptosis. As<SUB>2</SUB>O<SUB>3</SUB> induced apoptosis via both extrinsic and intrinsic apoptotic pathways by regulating the pro- or anti-apoptotic molecules. Moreover, As<SUB>2</SUB>O<SUB>3</SUB>-induced cell cycle arrested at G<SUB>2</SUB> phase in MDA-MB-231 cells. The study revealed that As<SUB>2</SUB>O<SUB>3</SUB> was a potent candidate for further investigation for combating against human breast tumour including the late stage breast tumour.}
    }